GLG News by Dermatologists (US)

Galderma has partnered with Anika to launch a hyaluronic acid product into the marketplace. It will be the first HA filler to be combined with Lidocaine.However, Medicis (with a 3 1/2 year headstart with Restylane) and Allergan's Juvederm will probably still take the lion's share of the filler market....

The phase 2 data for Incyclinide indicate a modest benefit over placebo for the 20 mg dose only, which drops off at 12 weeks. This drug will need a higher dose for efficacy. The premise behind a non antimicrobial antibiotic type medication is valid and intriguing. The next trial results are important...

This and other studies are highly suggestive that Gadolinium agents used in radiographic studies are associated with NFD. A large scale study should be initiated to confirm this association, and for now these agents should be avoided in patients with renal disease.

I totally agree with this article. The conclusions from the FDA are incorrect, and the data appear to indicate that the TCI's are actually protective!!!! In any event it has created a false sense of a problem, where none exists, and decreases the use of these agents, which are safer than the existing...

This article is a good summary of the currently available techniques of excision, subcision, and resurfacing. It does not mention dermal grafting, a technique that I personally use quite often. The maximum correction that one can achieve is 50-70% with a combination of multiple techniques.

1. P4P puts the burden on the physician without involving the patient.2. P4P creates yet another potential conflict of interest in patient care.3. P4P probably will not decrease costs or improve health.  

This product by Cytochroma is a vitamin D analog which is similar to Dovonex, a product that has been used for 13 years. Its efficacy is modest at best. This product may, repeat may be better, because it activates the vitamin D pathway, and inhibits catabolism of Vitamin D. Whether this makes the product...

This technology is new, but no better than other resurfacing technologies like Sciton and Fraxel. Pain is significant, healing takes weeks, and there are risks as in other resurfacing technologies. The final results are good. A head to head comparison with other technologies is needed.  

This article has validity in dermatology due to the increased resistance seen in acne. This may have clinical significance in that we may be seeing resistance to therapy in acne patients  after prolonged use.Collagenex corp. is developing non antibiotic medications for acne and rosacea that are...

The open label trial results for the product Relieva from Allegiance Equity Corp. are encouraging. However the trials need to be double blinded, and with a much larger number of patients. If the product can be compared to a low- mid potency topical steroid in efficacy, then it will be successful. Homeopathic...